INDV Q4 2023 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$293M+21.1% YoY

Gross Profit

$242M82.6% margin

Operating Income

$61M20.8% margin

Net Income

$54M18.4% margin

EPS (Diluted)

$0.38

QoQ Revenue Growth

+8.1%

Cash Flow

Operating Cash Flow

-$280M

Free Cash Flow

-$284M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.8B

Total Liabilities

$2.0B

Stockholders' Equity

-$191M

Cash & Equivalents

$316M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$293M	$242M	+21.1%
Gross Profit	$242M	$198M	+22.2%
Operating Income	$61M	-$258M	+123.6%
Net Income	$54M	-$183M	+129.5%